A Phase 3 interventional study of ezetimibe/simvastatin 10/40 and atorvastatin 40 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 33rd largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 31 in phase 3, and was the 33rd registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 13 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 75 interventional studies. Of the 69 that completed or were terminated, 33 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 77 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 44th largest by enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2008, is one of 58 in phase 3, and was the 68th registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 77 studies testing atorvastatin in Hypercholesterolemia, from their registry updates:
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participants currently taking atorvastatin 20 mg will be switched to either atorvastatin 40 mg or ezetimibe/simvastatin 10 mg/40 mg (10/40). After 6 weeks of treatment, the percent reduction in low-density lipoprotein cholesterol (LDL-C) will be assessed and compared between the two treatment groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
Drug: ezetimibe/simvastatin 10/40 · Drug: atorvastatin 20 mg
Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
Drug: atorvastatin 40 mg · Drug: atorvastatin 20 mg
ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
Also known as: Vytorin
atorvastatin 40 mg tablet once daily for 6 weeks
Also known as: Lipitor
All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
Also known as: Lipitor
Percent Change From Baseline in Low Density Lipoprotein (LDL)-C
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Number of Participants Reaching LDL-C Target Goals of <70 mg/dL
Target LDL-C level of \< 70 mg/dL (1.81 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
Time frame: Treatment Week 6
Number of Participants Reaching LDL-C Target Goal <77 mg/dL
Target LDL-C level of \< 77 mg/dL (2.00 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
Time frame: Treatment Week 6
Number of Participants Reaching LDL-C Target Goal <100 mg/dL
Target LDL-C level of \< 100 mg/dL (2.59 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
Time frame: Treatment Week 6
Percent Change From Baseline in Total Cholesterol
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Triglycerides
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Non-HDL Cholesterol
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Apolipoprotein B
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Apolipoprotein A-1
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in Apolipoprotein B/A-1 Ratio
Time frame: Baseline (Treatment Day 1), Treatment Week 6
Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
Time frame: Baseline (Treatment Day 1), Treatment Week 6
| Milestone | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Started | 120 | 130 |
| Completed | 116 | 125 |
| Not completed | 4 | 5 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 |
Target LDL-C level of \< 70 mg/dL (1.81 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
| participants | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Number of Participants Reaching LDL-C Target Goals of <70 mg/dL | 34 | 6 |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein (LDL)-C | -26.81 ± 27.09 | -11.81 ± 22.85 |
Target LDL-C level of \< 77 mg/dL (2.00 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
| participants | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Number of Participants Reaching LDL-C Target Goal <77 mg/dL | 45 | 11 |
Target LDL-C level of \< 100 mg/dL (2.59 mmol/L) at study endpoint after 6 weeks of treatment for the Full Analysis Set (FAS) population.
| participants | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Number of Participants Reaching LDL-C Target Goal <100 mg/dL | 81 | 52 |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol | -15.97 (-19.17 to -12.76) | -7.73 (-10.91 to -4.55) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Triglycerides | -5.41 (-11.36 to 0.95) | -7.54 (-13.32 to -1.38) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol | 5.37 (2.39 to 8.35) | 2.89 (-0.07 to 5.85) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-HDL Cholesterol | -22.50 (-26.78 to -18.22) | -10.88 (-15.13 to -6.64) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio | -28.77 (-33.78 to -23.76) | -12.66 (-17.63 to -7.69) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio | -18.63 (-22.37 to -14.89) | -8.60 (-12.31 to -4.89) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio | -24.41 (-29.40 to -19.43) | -11.20 (-16.15 to -6.25) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B | -17.23 (-20.84 to -13.62) | -9.53 (-13.12 to -5.95) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 | 2.56 (0.36 to 4.77) | -2.69 (-4.88 to -0.50) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B/A-1 Ratio | -18.59 (-22.70 to -14.48) | -5.67 (-9.76 to -1.59) |
| percent change from baseline | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg |
|---|---|---|
| Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP) | -6.18 (-20.49 to 10.70) | -8.86 (-22.67 to 7.41) |
Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe/Simvastatin 10/40 | — | 1/119 (0.8%) | 0/119 (0%) |
| Atorvastatin 40 mg | — | 1/130 (0.8%) | 2/130 (1.5%) |
| Placebo | — | 0/1 (0%) | 1/1 (100%) |
| Event | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg | Placebo |
|---|---|---|---|
| urinary tract infectionInfections and infestations | 1/119 | 0/130 | 0/1 |
| back painMusculoskeletal and connective tissue disorders | 0/119 | 1/130 | 0/1 |
| Event | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg | Placebo |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/119 | 2/130 | 1/1 |
| Age, Continuous(years) | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg | Total |
|---|---|---|---|
| Mean | 58.9 ± 10.0 | 59.7 ± 8.4 | 59.3 ± 9.2 |
| Sex: Female, Male(Participants) | Ezetimibe/Simvastatin 10/40 | Atorvastatin 40 mg | Total |
|---|---|---|---|
| Female | 57 | 65 | 122 |
| Male | 63 | 65 | 128 |
No study locations are listed for this record.
Plan to share: No
The record gives a start of Nov 2008, a primary completion of Sep 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin